Literature DB >> 1369102

Interleukin-6 is antiproliferative to a mouse hybridoma cell line and promotive for its antibody productivity.

F Makishima1, S Terada, T Mikami, E Suzuki.   

Abstract

Monoclonal antibody production by hybridoma cells at moderately slowed growth states would be favorable for commercial scale production since cells can devote their resources to performing the differentiated function, immunoglobulin production. We found that a purified recombinant human interleukin-6, which had been reported to support or stimulate proliferation of B cell hybridoma/plasmacytoma cells, suppressed growth of a hybridoma cell line in serum-free medium. In the presence of the interleukin, the growth-suppressed cells were viable for remarkably long periods in batch culture, and after removal of the interleukin from the culture medium, they started to proliferate at their normal growth rate. As the concentration of the interleukin increased in the culture, the growth rate decreased and the specific antibody productivity (antibody production rate per cell) increased to 5-fold of control at 10 U ml-1 (2 ng ml-1) of the interleukin.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1369102     DOI: 10.1007/bf00376096

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  21 in total

1.  Enhanced antibody production at slowed growth rates: experimental demonstration and a simple structured model.

Authors:  E Suzuki; D F Ollis
Journal:  Biotechnol Prog       Date:  1990 May-Jun

2.  A kinetic analysis of hybridoma growth and metabolism in batch and continuous suspension culture: effect of nutrient concentration, dilution rate, and pH.

Authors:  W M Miller; H W Blanch; C R Wilke
Journal:  Biotechnol Bioeng       Date:  1988-10-05       Impact factor: 4.530

3.  Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells.

Authors:  J Gauldie; C Richards; D Harnish; P Lansdorp; H Baumann
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

4.  Recombinant human interleukin 6 (B-cell stimulatory factor 2) is a potent inducer of differentiation of mouse myeloid leukemia cells (M1).

Authors:  C Miyaura; K Onozaki; Y Akiyama; T Taniyama; T Hirano; T Kishimoto; T Suda
Journal:  FEBS Lett       Date:  1988-07-04       Impact factor: 4.124

5.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

Authors:  K Ikebuchi; G G Wong; S C Clark; J N Ihle; Y Hirai; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

6.  Growth autonomy and tumorigenicity of interleukin 6-dependent B cells transfected with interleukin 6 cDNA.

Authors:  N Tohyama; H Karasuyama; T Tada
Journal:  J Exp Med       Date:  1990-02-01       Impact factor: 14.307

7.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

8.  Synthesis and secretion of light-chain immunoglobulin in two successive cycles of synchronized plasmacytoma cells.

Authors:  O Garatun-Tjeldsto; I F Pryme; J K Weltman; R M Dowben
Journal:  J Cell Biol       Date:  1976-02       Impact factor: 10.539

9.  B cell stimulating factor 2/interleukin 6 is a costimulant for human thymocytes and T lymphocytes.

Authors:  M Lotz; F Jirik; P Kabouridis; C Tsoukas; T Hirano; T Kishimoto; D A Carson
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

10.  Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas.

Authors:  J Van Snick; A Vink; S Cayphas; C Uyttenhove
Journal:  J Exp Med       Date:  1987-03-01       Impact factor: 14.307

View more
  11 in total

1.  Characterization and fed-batch culture of hybridoma overexpressing apoptosis suppressing gene bcl-2.

Authors:  S Terada; Y Itoh; H Ueda; E Suzuki
Journal:  Cytotechnology       Date:  1997-07       Impact factor: 2.058

2.  Enhanced IgG1 production by overexpression of nuclear factor kappa B inhibitor zeta (NFKBIZ) in Chinese hamster ovary cells.

Authors:  Masayoshi Onitsuka; Yukie Kinoshita; Akitoshi Nishizawa; Tomomi Tsutsui; Takeshi Omasa
Journal:  Cytotechnology       Date:  2017-11-29       Impact factor: 2.058

3.  Anti-apoptotic genes, bag-1 and bcl-2, enabled hybridoma cells to survive under treatment for arresting cell cycle.

Authors:  S Terada; K Fukuoka; T Fujita; T Komatsu; S Takayama; J C Reed; E Suzuki
Journal:  Cytotechnology       Date:  1997       Impact factor: 2.058

4.  Growth rate suppression of cultured mammalian cells enhances protein productivity.

Authors:  K Takahashi; S Tereda; H Ueda; F Makishima; E Suzuki
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

Review 5.  Methods and strategies available for the process control and optimization of monoclonal antibody production.

Authors:  P Fu; J P Barford
Journal:  Cytotechnology       Date:  1994       Impact factor: 2.058

6.  Establishing apoptosis resistant cell lines for improving protein productivity of cell culture.

Authors:  E Suzuki; S Terada; H Ueda; T Fujita; T Komatsu; S Takayama; J C Reed
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

7.  Growth control of hybridoma cells with an artificially induced EpoR-gp130 heterodimer.

Authors:  Masahiro Kawahara; Yuko Ogo; Kouhei Tsumoto; Izumi Kumagai; Hiroshi Ueda; Teruyuki Nagamune
Journal:  Cytotechnology       Date:  2006-12-05       Impact factor: 2.058

8.  Sericin, a protein derived from silkworms, accelerates the proliferation of several mammalian cell lines including a hybridoma.

Authors:  Satoshi Terada; Taeko Nishimura; Masahiro Sasaki; Hideyuki Yamada; Masao Miki
Journal:  Cytotechnology       Date:  2002-11       Impact factor: 2.058

9.  Co-expression of bcl-2 and bag-1, apoptosis suppressing genes, prolonged viable culture period of hybridoma and enhanced antibody production.

Authors:  S Terada; T Komatsu; T Fujita; A Terakawa; T Nagamune; S Takayama; J C Reed; E Suzuki
Journal:  Cytotechnology       Date:  1999-09       Impact factor: 2.058

10.  Enhanced antibody production of human-human hybridomas by retinoic acid.

Authors:  Y Inoue; M Fujisawa; M Shoji; S Hashizume; Y Katakura; S Shirahata
Journal:  Cytotechnology       Date:  2000-07       Impact factor: 2.058

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.